Lepu Biopharma Co., Ltd. Press Release


Lepu Biopharma: Puyouheng (pucotenlimab injection) obtains approval for marketing with a new indication, Breakthrough therapy designation granted by the CDE to MRG003 for the treatment of R/M NPC
Sep 29, 2022 15:40 JST
LEPU BIOPHARMA (2157.HK) announced that its first innovative biological drug, anti-PD-1 antibody - Puyouheng (generic name: pucotenlimab injection) has been approved for marketing by the National Medical Products Administration (NMPA) for the indication of unresectable or metastatic melanomas after the failure of previous systemic therapy.
More info..

Lepu Biopharma Co., Ltd. Successfully Listed on the Main Board of HKEX
Feb 23, 2022 18:11 JST
The biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157.HK), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange") today
More info..

Lepu Biopharma Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange
Feb 10, 2022 09:50 JST
The biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157), today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange").

More info..

Latest Release


More Latest Release >>